Literature DB >> 30899969

Correction to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Melanie J Davies1,2, David A D'Alessio3, Judith Fradkin4, Walter N Kernan5, Chantal Mathieu6, Geltrude Mingrone7,8,9, Peter Rossing10,11, Apostolos Tsapas12, Deborah J Wexler13,14, John B Buse15.   

Abstract

The affiliation details for Geltrude Mingrone are corrected below.

Entities:  

Year:  2019        PMID： 30899969     DOI： 10.1007/s00125-019-4845-x

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


  6 in total

1.  HWL-088, a new potent free fatty acid receptor 1 (FFAR1) agonist, improves glucolipid metabolism and acts additively with metformin in ob/ob diabetic mice.

Authors:  Yueming Chen; Qiang Ren; Zongtao Zhou; Liming Deng; Lijun Hu; Luyong Zhang; Zheng Li
Journal:  Br J Pharmacol       Date:  2020-02-08       Impact factor: 8.739

2.  Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial.

Authors:  Tina Vilsbøll; Ella Ekholm; Eva Johnsson; Ricardo Garcia-Sanchez; Nalina Dronamraju; Serge A Jabbour; Marcus Lind
Journal:  Diabetes Obes Metab       Date:  2020-02-23       Impact factor: 6.577

Review 3.  Kidney Disease in Diabetic Patients: From Pathophysiology to Pharmacological Aspects with a Focus on Therapeutic Inertia.

Authors:  Guido Gembillo; Ylenia Ingrasciotta; Salvatore Crisafulli; Nicoletta Luxi; Rossella Siligato; Domenico Santoro; Gianluca Trifirò
Journal:  Int J Mol Sci       Date:  2021-05-01       Impact factor: 5.923

4.  Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.

Authors:  Emil Ørskov Ipsen; Kasper S Madsen; Yuan Chi; Ulrik Pedersen-Bjergaard; Bernd Richter; Maria-Inti Metzendorf; Bianca Hemmingsen
Journal:  Cochrane Database Syst Rev       Date:  2020-11-19

5.  Study Protocol for Pleiotropic Effects and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.

Authors:  Yumie Takeshita; Takehiro Kanamori; Takeo Tanaka; Yuka Kaikoi; Yuki Kita; Noboru Takata; Noriho Iida; Kuniaki Arai; Tatsuya Yamashita; Kenichi Harada; Toshifumi Gabata; Hiroyuki Nakamura; Shuichi Kaneko; Toshinari Takamura
Journal:  Diabetes Ther       Date:  2020-01-20       Impact factor: 2.945

6.  Metformin may adversely affect orthostatic blood pressure recovery in patients with type 2 diabetes: substudy from the placebo-controlled Copenhagen Insulin and Metformin Therapy (CIMT) trial.

Authors:  Christian Stevns Hansen; Louise Lundby-Christiansen; Lise Tarnow; Christian Gluud; Christoffer Hedetoft; Birger Thorsteinsson; Bianca Hemmingsen; Niels Wiinberg; Simone B Sneppen; Søren S Lund; Thure Krarup; Sten Madsbad; Thomas Almdal; Bendix Carstensen; Marit E Jørgensen
Journal:  Cardiovasc Diabetol       Date:  2020-09-26       Impact factor: 9.951
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.